ADCs (Mab, ADA)
Antibody-drug conjugates or ADCs are an important class of highly potent biopharmaceutical drugs designed as a targeted therapy for the treatment of people with cancer. Unlike chemotherapy, ADCs are intended to target and kill only the cancer cells and spare healthy cells. ADCs are complex molecules composed of an antibody linked to a biologically active cytotoxic (anticancer) payload or drug. Antibody-drug conjugates are examples of bioconjugates and immunoconjugates.
SERVICES
- Antibody Drug Conjugate (ADC) Analysis
- Aggregate Analysis
- Size Exclusion Chromatography (SEC)
- Critical Reagent Characterization
- Pharmacodynamic (PD) Analysis
- Affinity Capture Elution (ACE) – Bridge Assay
- Cell Based Neutralizing Antibodies (Nabs)
- Fluorescence Testing
- Hybrid LC-MS/MS (Immunoaffinity LC-MS/MS)
- Immunogenicity Analysis
- Luminescence Testing
- Non-Clinical Non-GLP Sample Analysis
- Time Resolved Fluorescence
- Cell Culture Services
- Critical Reagents
- Method Transfer
- Method Development
- Method Qualification
- Method Validation
- Neutralizing Antibody (NAB) Studies
- Non-Clinical GLP Sample Analysis
- Pharmacodynamic (PD) Biomarkers
- Pharmacokinetic / Toxicokinetic (PK/TK) Analysis
- Polymeric Conjugate Testing
- Tissue Bioanalysis
- Multi-Plex Analysis
- Cell Sorting Services
- Cellular Phosphoflow Services
- Affinity Capture Elution (ACE) – Bridge Assay
- Molecular Services